Munit stands as a globally recognised leader in the micronization and milling of both small molecules and New Chemical Entities (NCEs) within the critical oncology pharmaceutical industry. Our advanced, GMP-compliant facilities, equipped with state-of-the-art technology, ensure precise and consistent results, crucial for the highly sensitive nature of oncological treatments.
These meticulously controlled processes are fundamental for enhancing the bioavailability and solubility of active pharmaceutical ingredients, leading to a faster onset of action, significantly improved therapeutic efficacy, and potentially reduced dosage requirements. By precisely increasing the surface area, our micronization techniques also boost the potency and performance of the active ingredient.
Munit offers highly customisable services with a broad range of particle size capabilities, all designed to ensure optimal drug delivery for oncological applications. Our expertise extends to supporting both small molecules and biological products, addressing their unique formulation challenges with unwavering commitment to quality and patient outcomes.